Prevalence of EGFR Mutations in Patients With Resected Stages I to III NSCLC: Results From the EARLY-EGFR Study.

Autor:	Soo RA; Department of Haematology-Oncology, National University Cancer Institute, National University Hospital, Singapore, Singapore. Electronic address: ross_soo@nuhs.edu.sg., Reungwetwattana T; Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand., Perroud HA; Department of Oncology, Sanatorio de la Mujer, Rosario, Argentina., Batra U; Department of Medical Oncology, Rajiv Gandhi Cancer Institute, Rohini, New Delhi, India., Kilickap S; Istinye University, Faculty of Medicine, Department of Medical Oncology, Liv Hospital, Ankara, Turkey., Tejado Gallegos LF; AstraZeneca, Evidence Generation Division, Mexico City, Mexico., Donner N; AstraZeneca, OBU Medical, Global Medical Affairs Division, Cambridge, United Kingdom., Alsayed M; AstraZeneca Pharmaceutical International, Dubai, United Arab Emirates., Huggenberger R; AstraZeneca International, Medical Department (Affairs), Baar, Switzerland., Van Tu D; Department of Optimal Therapy, Cancer Research and Clinical Trials Center, National Cancer Hospital, Hanoi, Vietnam.
Jazyk:	angličtina
Zdroj:	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2024 Oct; Vol. 19 (10), pp. 1449-1459. Date of Electronic Publication: 2024 Jun 14.
DOI:	10.1016/j.jtho.2024.06.008
Abstrakt:	Introduction: There is limited literature on the prevalence of EGFR mutations in early stage NSCLC. EARLY-EGFR (NCT04742192), a cross-sectional study, determined the prevalence of EGFR mutations in early stage NSCLC. Methods: This noninterventional, real-world study enrolled consecutive patients with resected stages IA to IIIB (American Joint Committee on Cancer eighth edition) NSCLC from 14 countries across Asia, Latin America, and the Middle East and Africa. The primary end point was prevalence of EGFR mutations and secondary end points included prevalence of EGFR mutation subtypes and treatment patterns. Results: Of 601 patients (median [range] age: 62.0 [30.0-86.0] y) enrolled, 52.7% were females and 64.2% were nonsmokers. Most had stages IA to IB NSCLC (64.1%) and adenocarcinoma (98.7%). Overall prevalence of EGFR mutations was 51.0%; most reported exon 19 deletions (48.5%) followed by exon 21 L858R mutations (34.0%). Women had a higher EGFR mutation rate than men (64.0% versus 36.4%). Compared with no EGFR mutations, patients with EGFR mutations were more likely to be nonsmokers (35.1% versus 60.9%) and have stage I NSCLC than stages II and III NSCLC (54.8% versus 47.3% and 35.6%). Systemic adjuvant therapy was planned in 33.8% of the patients with stages IB to IIIB disease and adjuvant chemoradiotherapy in 6.8%. Age above or equal to 60 years, females, and Asians were found to have a significantly (p < 0.05) higher odds of EGFR mutations, whereas smoking history and stage III disease had lower odds of EGFR mutations. Conclusions: The EARLY-EGFR study provides an overview of EGFR mutations and subtype prevalence in patients with early stage NSCLC. The study highlights the limited adherence to treatment guidelines suggesting an unmet need for improved adjuvant therapy. Competing Interests: Disclosure Dr. Ross Soo is on advisory board for Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, J INTS BIO, Janssen, Lily, Merck, Merck Serono, Novartis, Pfizer, Puma, Roche, Taiho, Takeda, Thermo Fisher, and Yuhan; and has received research grant from AstraZeneca and Boehringer Ingelheim. Dr. Thanyanan Reungwetwattana has received honoraria from AstraZeneca, Roche, Pfizer, Novartis, Merck Sharp & Dohme, Yuhan, Bristol Myers Squibb, and Takeda; is on the consulting or advisory board for AstraZeneca, Roche, Pfizer, Novartis, Merck Sharp & Dohme, Yuhan, Bristol Myers Squibb, and Takeda; participated in a speaker bureau for AstraZeneca, Roche, Pfizer, Novartis, Merck Sharp & Dohme, Bristol Myers Squibb, and Takeda; and received research funding from AstraZeneca, Roche, Novartis, Merck Sharp & Dohme, and Yuhan. Dr. Herman Andres Perroud reports a leadership role in Gior SRL; has received research funding from the Argentinean National Cancer Agency; and has received travel grants from Varifarma, Pfizer, and Raffo. Dr. Dao Van Tu has received honoraria from AstraZeneca, Roche, Merck Sharp & Dohme, Novartis, Pierre Fabre, and Merck; is on the consulting or advisory board for Merck Sharp & Dohme, AstraZeneca, Roche, Novartis, and Eisai; participated in a speaker bureau for AstraZeneca; and received travel grants from Merck. Dr. Luis Fernando Tejado Gallegos, Natalia Donner, Mohamed Elsayed, and Dr. Reto Huggenberger are employees at AstraZeneca. Dr. Saadettin Kilickap and Dr. Ullas Batra do not have any conflicts of interest to disclose. (Copyright © 2024 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu